Short‐term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps

Short‐term intensive insulin therapy is unique amongst therapies for type 2 diabetes because it offers the potential to preserve and improve beta‐cell function without additional pharmacological treatment. On the basis of clinical experience and the promising results of a series of studies in newly diagnosed patients, mostly in Asian populations, an expert workshop was convened to assess the available evidence and the potential application of short‐term intensive insulin therapy should it be advocated for inclusion in clinical practice. Participants included primary care physicians and endocrinologists. We endorse the concept of short‐term intensive insulin therapy as an option for some patients with type 2 diabetes at the time of diagnosis and have identified the following six areas where additional knowledge could help clarify optimal use in clinical practice: (1) generalizability to primary care, (2) target population and biomarkers, (3) follow‐up treatment, (4) education of patients and providers, (5) relevance of ethnicity, and (6) health economics. © 2014 The Authors. Diabetes Metabolism Research and Reviews published by John Wiley & Sons, Ltd.

[1]  C. Tack,et al.  Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT) , 2014, Diabetologia.

[2]  T. Ooi,et al.  Patient perspectives on discharge from specialist type 2 diabetes care back to primary care: a qualitative study. , 2014, Canadian journal of diabetes.

[3]  S. Andrikopoulos,et al.  Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology? , 2014, The Journal of endocrinology.

[4]  B. Zinman,et al.  Glycemic Variability in Patients With Early Type 2 Diabetes: The Impact of Improvement in β-Cell Function , 2014, Diabetes Care.

[5]  B. Zinman,et al.  Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. , 2013, American journal of physiology. Endocrinology and metabolism.

[6]  D. Birch,et al.  Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. , 2013, Canadian journal of surgery. Journal canadien de chirurgie.

[7]  Yanbing Li,et al.  Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus. , 2013, Diabetes technology & therapeutics.

[8]  B. Zinman,et al.  Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. , 2013, The lancet. Diabetes & endocrinology.

[9]  D. Owens.  Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes. , 2013, Diabetes technology & therapeutics.

[10]  B. Cha,et al.  The Effect of Early Intensive Insulin Therapy on Body Fat Distribution and β-Cell Function in Newly Diagnosed Type 2 Diabetes , 2013, Endocrine research.

[11]  J. Weng,et al.  Current role of short‐term intensive insulin strategies in newly diagnosed type 2 diabetes (短期胰岛素强化治疗策略对初诊2型糖尿病患者的作用) , 2013, Journal of diabetes.

[12]  J. Lasalle,et al.  Individualized glycaemic targets and pharmacotherapy in type 2 diabetes , 2013, Diabetes & vascular disease research.

[13]  F. Pouwer,et al.  Does the shortage of diabetes specialists in regional and rural Australia matter? Results from Diabetes MILES--Australia. , 2013, Diabetes research and clinical practice.

[14]  J. McGill,et al.  AACE comprehensive diabetes management algorithm 2013. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[15]  V. Siersma,et al.  Patients newly diagnosed with clinical type 2 diabetes mellitus but presenting with HbA1c within normal range: 19-year mortality and clinical outcomes. , 2013, Primary care diabetes.

[16]  P. Nilsson.  Early insulin treatment in type 2 diabetes , 2013 .

[17]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[18]  M. Hanefeld,et al.  Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial , 2013, Current Diabetes Reports.

[19]  S. Dalle,et al.  Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes. , 2013, Cellular signalling.

[20]  J. Holst,et al.  Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings , 2013, Diabetes, obesity & metabolism.

[21]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[22]  Suzanne L West,et al.  Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor‐based electronic health record , 2012, Pharmacoepidemiology and drug safety.

[23]  B. Zinman,et al.  Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function , 2012, Diabetes, obesity & metabolism.

[24]  Yanbing Li,et al.  Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. , 2012, Diabetes technology & therapeutics.

[25]  C. Deacon,et al.  Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis , 2012, Diabetes, obesity & metabolism.

[26]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[27]  P. Raskin,et al.  β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy , 2012, Diabetes Care.

[28]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[29]  B. Zinman,et al.  Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. , 2012, Journal of evaluation in clinical practice.

[30]  L. Zeng,et al.  Effects of a combination of oral anti‐diabetes drugs with basal insulin therapy on β‐cell function and glycaemic control in patients with newly diagnosed type 2 diabetes , 2012, Diabetes/metabolism research and reviews.

[31]  Yanbing Li,et al.  Attitudes Toward Diabetes Affect Maintenance of Drug-Free Remission in Patients With Newly Diagnosed Type 2 Diabetes After Short-Term Continuous Subcutaneous Insulin Infusion Treatment , 2012, Diabetes Care.

[32]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[33]  J. Weng,et al.  Short-Term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and β-Cell Function in Subjects With Long-Term Remission , 2011, Diabetes Care.

[34]  F. Rubino,et al.  Bariatric surgery: an IDF statement for obese Type 2 diabetes. , 2011, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[35]  W. Polonsky,et al.  Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population , 2011, Current medical research and opinion.

[36]  Ambady Ramachandran,et al.  A quantitative assessment of patient barriers to insulin , 2011, International journal of clinical practice.

[37]  S. Dwivedi,et al.  Recovery of β-cell functions with low-dose insulin therapy: study in newly diagnosed type 2 diabetes mellitus patients. , 2011, Diabetes technology & therapeutics.

[38]  B. Zinman,et al.  Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin , 2010, Diabetes, obesity & metabolism.

[39]  J. Leahy,et al.  Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.

[40]  Young Seol Kim,et al.  The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients , 2010, The Korean journal of internal medicine.

[41]  Ping-ping Li.  Could we use clinical benefit to evaluate the effects of chinese medicine on the treatment of cancer? , 2010, Chinese journal of integrative medicine.

[42]  B. Zinman,et al.  The response to short‐term intensive insulin therapy in type 2 diabetes , 2010, Diabetes, obesity & metabolism.

[43]  G. Nichols,et al.  Secondary Failure of Metformin Monotherapy in Clinical Practice , 2009, Diabetes Care.

[44]  Wen Xu,et al.  Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. , 2009, Chinese medical journal.

[45]  J. Chiasson.  Early Insulin Use in Type 2 Diabetes , 2009, Diabetes Care.

[46]  J. Colquitt,et al.  The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. , 2009, Health technology assessment.

[47]  P. Raskin,et al.  Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes , 2009, Diabetes Care.

[48]  M. Davidson.  Pro's and Con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation , 2009, Current opinion in endocrinology, diabetes, and obesity.

[49]  M. Karaca,et al.  Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. , 2009, Diabetes & metabolism.

[50]  M. Moodie,et al.  Cost-Effectiveness of Surgically Induced Weight Loss for the Management of Type 2 Diabetes: Modeled Lifetime Analysis , 2009, Diabetes Care.

[51]  T. Jap,et al.  Beneficial Effects of Insulin on Glycemic Control and β-Cell Function in Newly Diagnosed Type 2 Diabetes With Severe Hyperglycemia After Short-Term Intensive Insulin Therapy , 2008, Diabetes Care.

[52]  V. Sreenivas,et al.  Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. , 2008, Diabetes technology & therapeutics.

[53]  H. Tian,et al.  Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial , 2008, The Lancet.

[54]  G. Sundkvist,et al.  Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4‐year follow‐up , 2008, Diabetes, obesity & metabolism.

[55]  K. Maedler.  Beta cells in type 2 diabetes – a crucial contribution to pathogenesis , 2008, Diabetes, obesity & metabolism.

[56]  Ai-qun Ma,et al.  [Effect of short-term intensive treatment with insulin pump on beta cell function and the mechanism of oxidative stress in newly diagnosed type 2 diabetic patients]. , 2007, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[57]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[58]  余晓慧.  Effect of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients , 2007 .

[59]  B. Wajchenberg.  beta-cell failure in diabetes and preservation by clinical treatment. , 2007, Endocrine reviews.

[60]  P. Raskin,et al.  Insulin as Initial Therapy in Type 2 Diabetes , 2007, Journal of Investigative Medicine.

[61]  Haibing Chen,et al.  The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. , 2007, Diabetes research and clinical practice.

[62]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[63]  Yanbing Li,et al.  [Influencing factors for the curative effects of short-term continuous subcutaneous insulin infusion on newly diagnosed type 2 diabetes]. , 2005, Zhonghua yi xue za zhi.

[64]  S. Bonner-Weir,et al.  Five stages of evolving beta-cell dysfunction during progression to diabetes. , 2004, Diabetes.

[65]  J. Weng,et al.  Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. , 2004, Diabetes care.

[66]  S Del Prato,et al.  Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[67]  E. Ryan,et al.  Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. , 2004, Diabetes care.

[68]  G. Sundkvist,et al.  Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. , 2003, Diabetes care.

[69]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[70]  B. Glaser,et al.  Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment , 1997, Diabetes Care.

[71]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[72]  M. Shichiri,et al.  Effects of early introduction of intensive insulin therapy on the clinical course in non-obese NIDDM patients. , 1995, Diabetes research and clinical practice.

[73]  Yanbing Li,et al.  Fasting plasma glucose after intensive insulin therapy predicted long-term glycemic control in newly diagnosed type 2 diabetic patients. , 2013, Endocrine journal.

[74]  J. Shaw,et al.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.

[75]  B. Wajchenberg.  Clinical approaches to preserve beta-cell function in diabetes. , 2010, Advances in experimental medicine and biology.

[76]  H. Tian,et al.  [The effects of early intensive therapy on islet beta cell function and long-term glycemia control in newly diagnosed type 2 diabetic patients with different fasting plasma glucose levels.]. , 2010, Zhonghua nei ke za zhi.

[77]  V. Grill,et al.  Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: a 6-year follow-up study. , 2010, The review of diabetic studies : RDS.

[78]  Li Yan.  The effects of short-term continuous subcutaneous insulin infusion treatment on beta-cell function in newly diagnosed type 2 diabetic patients , 2003 .